



Pherecydes Pharma organizes a scientific symposium during the 23rd National Days of Infectiology

Phage therapy in 2022: French experience

Paris, June 8, 2022 - 6:00 pm CEST - Pherecydes Pharma (FR0011651694 - ALPHE, PEA-PME eligible), a biotech company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces it will participate to the scientific symposium "Phage therapy: French experience", which will be held on **June 15, 2022 from 5:15 pm to 6:30 pm in the amphitheater A of the Palais des Congrès in Bordeaux, as part of the 23rd National Days of Infectiology (NDI).**

The symposium, moderated by Dr. F.-A. Dauchy from the Bordeaux University Hospital, will host the following presentations:

- Phagotherapy and IOA. Compassionate cases and clinical studies including PhagoDAIR: Pr. T. Ferry (Lyon)
- Phage therapy and Infections of the Diabetic Foot Ulcer. State of knowledge. PhagoPied: Pr. A. Sotto (Nîmes)
- Phage therapy and pulmonary infections. Preclinical results. Planned clinical studies: Dr. A. Bleibtreu (Paris)

Pascal Birman, Medical Director of Pherecydes Pharma, comments: *"Antibiotic resistance is a major public health issue and is a central theme at this 23rd edition of the NDI. This symposium is an opportunity to highlight the interest of phage therapy through several clinical studies that will be conducted in different indications and through compassionate treatments already performed with our phages. Pherecydes Pharma and its partners are doing their utmost to ensure that these studies provide useful answers to improve the treatment of patients suffering from antibiotic resistant infections."*

About Pherecydes Pharma

Founded in 2006, Pherecydes Pharma is a biotechnology company that develops treatments against resistant bacterial infections, responsible for many serious infections. The Company has developed an innovative approach, precision phage therapy, based on the use of phages, natural bacteria-killing viruses. Pherecydes Pharma is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two thirds of hospital-acquired resistant infections: *Staphylococcus aureus*, *Escherichia coli* and *Pseudomonas aeruginosa*. The concept of precision phage therapy has been successfully applied in several dozen patients in the context of compassionate use, under the supervision of the French National Agency for the Safety of Medicines (ANSM). Headquartered in Nantes, Pherecydes Pharma has a team of around twenty experts from the pharmaceutical industry, biotechnology sector and academic research.

For more information, www.pherecydes-pharma.com



Contacts

Pherecydes Pharma

Thibaut du Fayet

Deputy CEO

investors@pherecydes-pharma.com

NewCap

Dusan Oresansky

Investor Relations

pherecydes@newcap.eu

T.: +33 1 44 71 94 92

NewCap

Arthur Rouillé

Media Relations

pherecydes@newcap.eu

T.: +33 1 44 71 00 15

Disclaimer

This press release contains non-factual elements, including, but not limited to, certain statements regarding future results and other future events. These statements are based on the current vision and assumptions of the management of the Company. They incorporate known and unknown risks and uncertainties that could result in significant differences in results, profitability and expected events. In addition, Pherecydes Pharma, its shareholders and its affiliates, directors, officers, counsels and employees have not verified the accuracy of, and make no representations or warranties about, statistical information or forecast information contained within this news release and that originates or is derived from third party sources or industry publications; these statistical data and forecast information are only used in this press release for information purposes. Finally, this press release may be drafted in French and in English. In the event of differences between the two texts, the French version will prevail.